

**REMARKS**

**I. Amendments**

This application is the U.S. national stage of PCT/SE2004/001013 (the "PCT application"), filed on June 23, 2004.


Claims 1-3, 5, 7, and 8 have been amended to place the claims in conformance with U.S. patent practice. Claim 3 has been amended to recite an option step of converting the compound of Formula I into a pharmaceutically acceptable salt. Support for this amendment is provided by Example 3 at page 12. Claims 4 and 6 have been cancelled.

Upon entry of this Preliminary Amendment, claims 1-3, 5, 7, and 8 are pending. No new matter has been added by any amendment herein.

This Preliminary Amendment is being filed concurrently with a new patent application. If any fee is required in connection with this communication, the Assistant Commissioner is authorized to charge such fee to Deposit Account No. 23-1703.

Dated: Dec. 19, 2005

Respectfully submitted,



Andrew Fessak,  
Reg. No. 48,528  
Customer No. 007470  
White & Case LLP  
Direct Dial: (212) 819-8437